Percheron Therapeutics Ltd
Percheron Therapeutics Limited is an Australia-based biotechnology company.
The business
Percheron Therapeutics Limited is an Australia-based biotechnology company. The Company is focused on the development and commercialization of novel therapies for oncology and rare diseases. The Company’s lead program is HMBD-002, a monoclonal antibody targeting the immune checkpoint regulator, VISTA. HMBD-002 has completed a phase I clinical trial in patients with advanced cancer. HMBD-002 is a recombinant humanized monoclonal IgG4 antibody to human v-domain immunoglobulin suppressor of T-cell activation (VISTA). VISTA is one of a number of novel immuno-oncology targets under investigation by pharmaceutical companies, with potential applications to a range of solid tumors and hematological malignancies.
Small Caps Research
No research on Percheron Therapeutics Ltd yet
We cover the ASX small-cap market one company at a time. Request coverage and we’ll prioritise PER based on demand.
Share price
Market Statistics
Valuation
Trading Activity
Performance
Latest news
Percheron Therapeutics acquires worldwide licence to commercialise HMBD-002 cancer therapy
Percheron Therapeutics (ASX: PER) has acquired a worldwide exclusive license from Singapore-based Hummingbird Bioscience for monoclonal antibody therapy HMBD-002 to treat a range of cancer indications. The company will pay Hummingbird an upfront consideration of $4.6 million plus milestone payments of as much as $443m and royalties on net sales of the commercial product. Percheron […]
Percheron Therapeutics completes toxicology study for avicursen ahead of US FDA discussions
Australian biotechnology company Percheron Therapeutics (ASX: PER) has completed a nine-month toxicology study in non-human primates for its lead program, avicursen. Avicursen is an antisense oligonucleotide that targets the CD49d biomarker. The study, which commenced in March 2023, concluded its final dosing on schedule in December. Recovery phase The majority of subjects in the study […]
Looking for charts & signals? See the tab.
Unlock the full research library - free.
Create a free account to access every broker report, CEO interview, IPO alert, and daily market wrap. No credit card. No paywall.